Pfizer (PFE) is scheduled to report Q4 earnings before the market open on Tuesday January 29, with a conference call scheduled for 10:00 am ET. Pfizer is a biopharmaceutical company that engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide... EXPECTATIONS: Analysts are looking for EPS of 44c on revenue of $14.4B, according to First Call. The consensus range for EPS is 43c-47c on revenue of $13.94B-$14.66B... LAST QUARTER: Pfizer reported Q3 EPS of 53c against estimates of 53c on revenue of $14B against estimates of $14.64B. At the time of its Q3 earnings release, the drug giant gave FY12 EPS guidance $2.14-$2.17 on a consensus of $2.21. Note that consensus estimates for FY12 have since been reduced to $2.16... STREET RESEARCH: On December 31, Leerink Swann said it believes Bristol-Myers (BMY) and Pfizer's (PFE) Eliquis was approved with a solid label and is positioned to be the leader for stroke prevention in atrial fibrillation... PRICE ACTION: Pfizer shares are trading close to a 52-week high of $27.30, which was reached on January 24. Shares are up about 8% in the month of January. In early afternoon trading, Pfizer shares are near flat at ~$27.